羟基脲 T0676

Product Introduction
Bioactivity


英文名: Hydroxyurea

描述: Hydroxyurea (Hydroxycarbamide) 是一种抗肿瘤剂，通过抑制核糖核苷二磷酸还原酶来抑制 DNA 合成。

细胞实验: Erythroid cells obtained from peripheral blood of the same patients(Thirteen β-Thal/HbE patients are treated with hydroxyurea orally for 2 years at a starting dose of 5 mg/kg/day for 5 days/week with escalation to a maximum of 10 mg/kg/day) 1 year after they had stopped hydroxyurea treatment are treated with hydroxyurea in vitro.Treatment of cells performs in primary culture with 30 μM hydroxyurea for 96 hours.(Only for Reference)

体外活性: Hydroxyurea能够抑制HIV-1复制。体外实验显示，对激活的PBMC中HIV-1实验室株，Hydroxyurea的90%抑制浓度（IC90）为0.4 mM。研究还发现Hydroxyurea与核苷逆转录酶抑制剂二氮嘧啶（didanosine）具有协同增效作用，可通过减小脱氧核苷三磷酸池大小来抑制激活PBMC中的HIV-1复制。Hydroxyurea已被证实能增敏对二氮嘧啶耐药的突变体[1][2]。Hydroxyurea在镰状细胞性贫血治疗中显示出活性，它通过增加胎儿血红蛋白的产量，从而减少了患者的溶血现象。Hydroxyurea通过抑制核糖核苷酸还原酶（负责核糖核苷酸向脱氧核糖核苷酸转换的速率限制酶）展现其细胞静止效果，促进细胞分裂在S期被阻断[1]。

体内活性: Hydroxyurea 治疗在17周内持续降低WBC(白细胞)和ANC(绝对中性粒细胞)计数，但并未改善贫血症状。而以每公斤体重50 mg剂量的 Hydroxyurea 较之于对照化合物处理的镰状细胞鼠，WBC和ANC计数减少，但对贫血无改善效果[5]。

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 60 mg/mL (788.95 mM)
H2O : 55 mg/mL (723.11 mM)


关键字: Inhibitor | Autophagy | Human immunodeficiency virus | inhibit | HIV | Apoptosis | DNA/RNA Synthesis | Hydroxyurea

相关产品: Tubulin polymerization-IN-43 | KH16 | Umbelliferone | Lucidenic acid B | Gliotoxin | GS-444217 | AOH1996 | Zeylenone | MDK83190 | YH239-EE

相关库: Drug Repurposing Compound Library | Anti-Cancer Drug Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Anti-Cancer Active Compound Library | Anti-Cancer Approved Drug Library | Apoptosis Compound Library | DNA Damage & Repair Compound Library | Chemotherapy Drug Library | Anti-Infection Compound Library

羟基脲 T0676信息由TargetMol中国为您提供，如您想了解更多关于羟基脲 T0676报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途